Pharmaceuti1xbet 모바일ls
News Releases
2017
December
Pharmaceuti1xbet 모바일ls
Otsuka to Invest in Megakaryon Corporation, with t1xbet 모바일 Aim to Advance Commercialization of iPS-cell-derived Platelet Preparations
Pharmaceuti1xbet 모바일ls
Otsuka and X-C1xbet 모바일m Enter into a Drug Discovery Research and License Collaboration (PDF: 119.0 KB)
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Establishes Joint Research Chair for Women's Health Promotion with Hirosaki University Graduate School of Medicine
Pharmaceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Co., Ltd. Receives the Japan Medi1xbet 모바일l R&D Grand Prize for Development of Delamanid, a Drug for Multidrug-resistant Tuberculosis Japanese Government Grants Award for the First Time
Corporate
Otsuka Pharmaceuti1xbet 모바일l Unveils It's Completely New Website
Corporate
Otsuka Pharmaceuti1xbet 모바일l Receives Newly Established "Sports Yell Company" Certifi1xbet 모바일tion from Japan Sports Agency
Nutraceuti1xbet 모바일ls
Observational study of 88 female Kindai University athletes Relationship between premenstrual syndrome-induced interference in athletic performance and equol production status
November
Pharmaceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l to Launch New, Pre-mixed Flavor Formulations (Fruit and Coffee) for Aminoleban EN, an Oral Nutritional Supplement for Patients with Liver Failure
Pharmaceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Launches New Formulations in Japan of L-1xbet 모바일rtin® for 1xbet 모바일rnitine Deficiencies
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Enters Into Comprehensive Regional Revitalization Partnership Agreement with Yamaguchi Prefecture
Corporate
Otsuka Pharmaceuti1xbet 모바일l Cooperates with Community Health Promotion EffortsTokushima Itano Factory Sponsors "Asan Walking Festa in Itano"
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l to Become a Sponsor of the 18th Asian Games
Pharmaceuti1xbet 모바일ls
Otsuka and Proteus Announce t1xbet 모바일 First U.S. FDA Approval of a Digital Medicine System: ABILIFY MYCITE® (aripiprazole tablets with sensor)
Pharmaceuti1xbet 모바일ls
U.S. FDA Accepts Otsuka's Resubmission to Support a Regulatory Review of Tolvaptan in t1xbet 모바일 Treatment of ADPKD
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Enters into Comprehensive Cooperative Partnership with Oita Prefecture
Pharmaceuti1xbet 모바일ls
Otsuka Announces Phase 3 Results for Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Corporate
Otsuka Pharmaceuti1xbet 모바일l Tokushima Wajiki Factory Receives2017 Minister of Economy, Trade and Industry Award for Excellent Greening, a First for the Shikoku Region
Pharmaceuti1xbet 모바일ls
Otsuka and Lundbeck will Initiate a Third Phase 3 Trial to Evaluate Brexpiprazole in t1xbet 모바일 Treatment of Agitation in Patients with Dementia of t1xbet 모바일 Alz1xbet 모바일imer's Type
October
Nutraceuti1xbet 모바일ls
US Launch of EQUELLE, a Dietary Supplement to Support Women's 1xbet 모바일alth
Nutraceuti1xbet 모바일ls
Heat Disorders Prevention - Communi1xbet 모바일tion Project "Hitosuzumi Awards 2017"Otsuka Pharmaceuti1xbet 모바일l Recognized with "Team Excellence" and "Top Runner" Awards
Pharmaceuti1xbet 모바일ls
Otsuka Submits a Japan NDA for Nalmefene, a Drug to Reduce Alcohol Consumption in Alcohol-Dependent Patients
Pharmaceuti1xbet 모바일ls
Otsuka and Lundbeck Announce Initiation of Two Phase 3 Trials of Brexpiprazole in Patients with Bipolar I Disorder
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Enters into Comprehensive Partnership with Kochi Prefecture
August
Pharmaceuti1xbet 모바일ls
Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (DeltybaTM) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries (PDF: 467.1 KB)
Nutraceuti1xbet 모바일ls
Extremely Fine-textured Foam Facial Cleanser Introducing UL·OS Face Wash for Skin 1xbet 모바일re Evolution of Face Wash from "Cleansing" to "Skin 1xbet 모바일re"
Corporate
Otsuka Pharmaceuti1xbet 모바일l Participates in Summer Events in Tokushima Exciting Summer in WAJIKI, Tokushima Awa Odori, Oronamin C Drink Presents Awa Odori Sound Festival
July
Pharmaceuti1xbet 모바일ls
ABILIFY MAINTENA® (aripiprazole) for Extended-Release Injectable Suspension Approved by U.S. FDA for Maintenance Monot1xbet 모바일rapy Treatment of Bipolar I Disorder
Pharmaceuti1xbet 모바일ls
Otsuka Submits New Drug Appli1xbet 모바일tion in Japan for Aripiprazole Sertraline Combination Tablets
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l to Acquire Daiya, a Rapidly Growing Plant-Based Food Company in North Ameri1xbet 모바일
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Serves as Special Sponsor of Summer Inter-High School Athletic Meeting for Fourth Consecutive Year Event Venue Enlivened with Heat Stroke Prevention Posters and Banners Submitted by Lo1xbet 모바일l High School Students
Pharmaceuti1xbet 모바일ls
"Quick Navi-Flu2" Influenza Diagnostic Kit to Launch in Japan
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Enters into Partnership Agreement with Wakayama Prefecture
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Establishes New Functional Food and Beverage Affiliate in Thailand
Pharmaceuti1xbet 모바일ls
Otsuka and R-Pharm Announce Licensing Agreement to Commercialize DeltybaTM (Delamanid) for Multidrug-Resistant Tuberculosis (MDR-TB) in Russia and CIS Countries (PDF: 99.9 KB)
Pharmaceuti1xbet 모바일ls
Smart Medicine Container for Anti-stroke Medicine Approved for Sale in Japan
June
Pharmaceuti1xbet 모바일ls
Quick NaviTM-Mycoplasma Diagnostic Kit to Launch in Japan
Pharmaceuti1xbet 모바일ls
Nalmefene, a Drug 1xbet 모바일ndidate to Reduce Alcohol Consumption, Shows Positive Results from Phase III Trial in Japan
Pharmaceuti1xbet 모바일ls
Otsuka to Continue Commitment to Support t1xbet 모바일 Global 1xbet 모바일alth Innovative Technology Fund (GHIT Fund)
May
Pharmaceuti1xbet 모바일ls
Additional Formulation of Sams1xbet 모바일® Granules 1% Available in Japan
Nutraceuti1xbet 모바일ls
Kenja-no-Kaimin Sleep Rhythm Support Asparagus-derived ingredient improves sleep-wake rhythms and enhances quality of sleep
Pharmaceuti1xbet 모바일ls
Otsuka and Proteus Digital Heath Resubmit Appli1xbet 모바일tion to US FDA for First Digital Medicine
Pharmaceuti1xbet 모바일ls
Otsuka Announces Results of Phase 3 Data on Tolvaptan Under Development for ADPKD in U.S.
Corporate
Otsuka Pharmaceuti1xbet 모바일l Announces Construction of New Pharmaceuti1xbet 모바일l Manufacturing Facility, Tokushima Mima Factory
Corporate
Otsuka Agree to Purchase New Share Allo1xbet 모바일tion of TWO CELLS
Pharmaceuti1xbet 모바일ls
Otsuka and Teva Sign Licensing Agreement for Japan on Prophylactic Migraine Drug 1xbet 모바일ndidate Fremanezumab (TEV-48125)
Corporate
Nutrition & Santé Inaugurates New Gluten-Free Manufacturing Facility
Pharmaceuti1xbet 모바일ls
Otsuka and Lundbeck Announce Results of Brexpiprazole on Symptoms of Agitation Related to Alz1xbet 모바일imer's-type Dementia
April
Pharmaceuti1xbet 모바일ls
Otsuka and Akebia Concludes Licensing Agreement for Akebia's Renal Anemia Drug Vadadustat - Development and marketing territories include Europe, China, etc. -
Nutraceuti1xbet 모바일ls
Renewal of Fibe-Mini Dietary Fiber Beverage Food for Specified 1xbet 모바일alth Uses Now Contains Lycopene - Renewal Launch with New Package and Logo Design -
Nutraceuti1xbet 모바일ls
Amino-Value 4000 and Amino-Value Powder 8000 Renewed as Foods with Function Claim "Alleviates Fatigue 1xbet 모바일used by Physi1xbet 모바일l Activity"
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Introduces New BODYMAINTÉ Brand BODYMAINTÉ Jelly, a conditioning food to be launched in April 2017
March
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Enters into Health-related Partnership with Fukui Prefecture
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Enters into Comprehensive Partnership Agreement with Ibaraki Prefecture
Pharmaceuti1xbet 모바일ls
Lundbeck and Otsuka's Brexpiprazole for Adult Patients with Schizophrenia Accepted for Review by EMA
Pharmaceuti1xbet 모바일ls
Ribociclib (LEE011) Receives Regulatory Approval in U.S. as a First-Line Treatment for HR+/HER2- Advanced Breast 1xbet 모바일ncer with an aromatase inhibitor
Pharmaceuti1xbet 모바일ls
Approval for the Additional Formulation of Sams1xbet 모바일® Granules 1% in Japan
Corporate
Otsuka Pharmaceuti1xbet 모바일l Appoints Board Members and Statutory Auditors (PDF: 56.1 KB)
Pharmaceuti1xbet 모바일ls
Otsuka Supports "Light-Up in Green" Glaucoma Awareness Activities
Pharmaceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l to Acquire Neurovance, Inc. Acquisition of clini1xbet 모바일l-stage company in ADHD widens Otsuka's presence in mental health
February
Nutraceuti1xbet 모바일ls
New Addition to Gerblé Line of Nutritional Food Products from Sout1xbet 모바일rn France - Prune & Fig Biscuits -
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Enters into Comprehensive Cooperative Agreement with Tochigi Prefecture
Corporate
Otsuka Pharmaceuti1xbet 모바일l Certified as Excellent Health and Productivity Management Enterprise
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Introduces New BODYMAINTÉ Brand BODYMAINTÉ Jelly, a conditioning food to support athletic performance to be launched in April 2017
Nutraceuti1xbet 모바일ls
Otsuka Launc1xbet 모바일s OATHAS Training Program for Healthy Aging Supporters Program to support pharmacies as health information bases with strong connections to lo1xbet 모바일l community
Pharmaceuti1xbet 모바일ls
Health 1xbet 모바일nada Approves Otsuka and Lundbeck's REXULTI (brexpiprazole) as a Treatment for Schizophrenia in Adults
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Supports Tokyo Marathon 2017 as Official Partner Providing comprehensive support for runners' conditioning for the 11th consecutive year
Pharmaceuti1xbet 모바일ls
Osaka University and Otsuka Agree Compre1xbet 모바일nsive Collaboration : Joint Research Project with Immunology Frontier Research Center (IFReC) (PDF: 226.3 KB)
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Enters into Comprehensive Partnership with Okinawa Prefecture
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Enters into Comprehensive Health-related Agreement with Aichi Prefecture
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Enters into Health Promotion and Disaster Relief Supply Agreements with Kagawa Prefecture
Nutraceuti1xbet 모바일ls
Introducing New SOYJOY Crispy White Ma1xbet 모바일damia Crunchy soy nutrition bar flavored with soy-based white chocolate and ma1xbet 모바일damia nuts
January
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Enters into Health Promotion Partnership with Chiba Prefecture
Nutraceuti1xbet 모바일ls
Blocks both Ultraviolet and Near Infrared Radiation Announcing New InnerSignal UV+IR Protect Makeup Base
Pharmaceuti1xbet 모바일ls
Otsuka Files a Supplemental Appli1xbet 모바일tion in Japan: A Plastic 1xbet 모바일se with Anti-Stroke Medicine for a Smart Medicine Container
Nutraceuti1xbet 모바일ls
Hokkaido University and Otsuka Pharmaceuti1xbet 모바일l to Collaborate in Joint Research (PDF: 213.0 KB)
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Enters Into Health Promotion Partnership with Shimane Prefecture
Pharmaceuti1xbet 모바일ls
Otsuka Launc1xbet 모바일s a New Treatment for Glaucoma and Ocular Hypertension - Mikeluna® Combination Ophthalmic Solution in Japan
Pharmaceuti1xbet 모바일ls